CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of
tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. has a license, development, and commercialization agreement with United Therapeutics Corporation for 3D bioprinting of solid-organ scaffolds for human transplants. The company is headquartered in Ness Ziona, Israel. The company trades on NASDAQ exchange. The company headquarter is located in Ness Ziona, . The company was established in the 2004.
| Ticker | CLGN |
| Long Name | CollPlant Holdings Ltd. |
| Short Name | CollPlant |